

- Chandrasekharappa S, Teh B. Clinical and molecular aspects of multiple endocrine neoplasia type 1. In: Dahia PLM, Eng C, eds. *Genetic Disorders of Endocrine Neoplasia*, Vol. 28. Front Horm Res. Basel: Switzerland: Karger; 2001:50–80.
- Kouvaraki MA, Lee JE, Shapiro SE, et al. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. *Arch Surg* 2002;137:641–647.
- Brandi M, Gagel R, Angeli A, et al. Consensus guidelines for diagnosis and therapy of MEN type 1 and type 2. *J Clin Endocrinol Metab* 2001;86:5658–5671.
- Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia type 1 (MEN 1) gene. *Science* 1997;276:404–407.
- Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). *QJM* 1996;89:653–669.
- Carty SE, Helm AK, Amico JA, et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. *Surgery* 1998;124:1106–1114.
- Machens A, Schaaf L, Karges W, et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): A multicentre study of 258 gene carriers. *Clin Endocrinol (Oxf)* 2007;67:613–622.
- Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). In: DeGroot LJ, Besser GK, Burger HG, et al, eds. *Endocrinology*. Philadelphia, PA: WB Saunders; 1995; 275–294.
- Brandi ML, Marx SJ, Aurbach GD, et al. Familial multiple endocrine neoplasia type 1. A new look at pathophysiology. *Endocrinol Rev* 1987;8:391–405.
- Benson L, Ljunghall S, Akerstrom G, et al. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. *Am J Med* 1987;82:731–737.
- Agha A, Carpenter R, Bhattacharya S, et al. Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: Two case reports of an unrecognized entity. *J Endocrinol Invest* 2007;30:145–149.
- Shih RY, Fackler S, Maturro S, et al. Parathyroid carcinoma in multiple endocrine neoplasia type 1 with a classic germline mutation. *Endocr Pract* 2009;15:567–572.
- Sato M, Miyauchi A, Namihira H, et al. A newly recognized germline mutation of MEN1 gene identified in a patient with parathyroid adenoma and carcinoma. *Endocrine* 2000;12:223–226.
- Pipeleers-Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenum of patients with multiple endocrine neoplasia type 1 and the Zollinger–Ellison syndrome. *N Engl J Med* 1990;322:723–727.
- Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger–Ellison syndrome. *N Engl J Med* 1999;341:635–644.
- Weber H, Venzon D, Lin J, et al. Determinants of metastatic rate and survival in patients with Zollinger–Ellison syndrome: A prospective long-term study. *Gastroenterology* 1995;108:1637–1649.
- Skosgeid B, Rastad J, Öberg K. Multiple endocrine neoplasia type 1. Clinical features and screening. *Endocrinol Metab Clin N Am* 1994;23:1–18.
- Marx SJ. Multiple endocrine neoplasia type 1. In: Vogelstein B, Kinzler KW, eds. *The Genetic Basis of Human Cancer*. New York City: McGraw Hill; 2002:475–499.
- Thomas-Marques L, Murat A, Delemer B, et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. *Am J Gastroenterol* 2006;101:266–273.
- Corbetta S, Pizzocaro A, Peracchi M, et al. Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types. *Clin Endocrinol (Oxf)* 1997;47:507–512.
- Pieterman CR, Schreinemakers JM, Koppeschaar HP, et al. Multiple endocrine neoplasia type 1 (MEN1): Its manifestations and effect of genetic screening on clinical outcome. *Clin Endocrinol (Oxf)* 2009;70:575–581.
- Gibril F, Schumann M, Pace A, et al. Multiple endocrine neoplasia type 1 and Zollinger–Ellison syndrome: A prospective study of 107 cases and comparison with 1009 cases from the literature. *Medicine (Baltimore)* 2004;83:43–83.
- Larsson C, Skosgeid B, Öberg K, et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. *Nature* 1988;332:85–87.
- Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): Analysis of 1336 mutations reported in the first decade following identification of the gene. *Hum Mutat* 2008;29:22–32.
- Giraud S, Zhang CX, Serova-Sinilnikova OM, et al. Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. *Am J Hum Genet* 1998;63:455–467.
- Wautot V, Vercherat C, Lespinasse J, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: Search for correlation between phenotype and the functional domains of the MEN1 protein. *Hum Mutat* 2002;20:35–47.
- Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger–Ellison syndrome. Clinical presentation in 261 patients. *Medicine (Baltimore)* 2000;79:379–411.
- Bardram L, Stage JG. Frequency of endocrine disorders in patients with the Zollinger–Ellison syndrome. *Scand J Gastroenterology* 1985;20:233–238.
- Uchino S, Noguchi S, Sato M, et al. Screening of the MEN1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. *Cancer Res* 2000;60:5553–5557.
- Scheithauer BW, Laws ERJ, Kovacs K, et al. Pituitary adenomas of the multiple endocrine neoplasia type 1 syndrome. *Semin Diagn Pathol* 1987;4:205–211.
- Newey PJ, Thakker RV. Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. *Endocr Pract* 2011;17:8–17.
- Pieterman CR, van Hulsteijn LT, den Heijer M, et al. Primary hyperparathyroidism in MEN1 patients: A cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype. *Ann Surg* 2012;255:1171–1178.
- Pieterman CR, Vriens MR, Dreijerink KM, et al. Care for patients with multiple endocrine neoplasia type 1: The current evidence base. *Fam Cancer* 2010;10:157–171.
- Pacini F, Castagna MG, Cipri C, et al. Medullary thyroid carcinoma. *Clin Oncol (R Coll Radiol)* 2010;22:475–485.
- Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association. *Thyroid* 2009;19:565–612.
- Fuchshuber PR, Looze TR, Hicks WL Jr, et al. Medullary carcinoma of the thyroid: Prognostic factors and treatment recommendations. *Ann Surg Oncol* 1998;5:81–86.
- Dottoni ME, Assi A, Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. *Cancer* 1996;77:1556–1565.
- Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. *Cancer* 2000;88:1139–1148.
- Kraimps JL, Denizot A, Carnaille B, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type IIA: Retrospective French multicentric study. Groupe d'Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. *World J Surg* 1996;20:808–812; discussion 812–813.
- Eng C, Mulligan LM, Smith DP, et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. *Clin Endocrinol (Oxf)* 1995;43:123–127.
- Wohlk N, Cote GJ, Bugalho MM, et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1996;81:3740–3745.
- National Comprehensive Cancer Network. *The NCCN Clinical Practice Guidelines in Oncology: Thyroid Cancer* (Version 2.2012). 2012. www.NCCN.org.
- Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. *JAMA* 1996;276:1575–1579.
- Morrison PJ, Nevin NC. Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome). *J Med Genet* 1996;33:779–782.
- Brauckhoff M, Gimm O, Weiss CL, et al. Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: Clinical manifestation and course in early and late onset disease. *World J Surg* 2004;28:1305–1311.
- Mole SE, Mulligan LM, Healey CS, et al. Localisation of the gene for multiple endocrine neoplasia type 2A to a 480 kb region in chromosome band 10q11.2. *Hum Mol Genet* 1993;2:247–252.
- Gardner E, Papi L, Easton DF, et al. Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2. *Hum Mol Genet* 1993;2:241–246.
- Takahashi M, Asai N, Iwashita T, et al. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations. *J Intern Med* 1998;243:509–513.
- Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: Which test is best? *JAMA* 2002;287:1427–1434.
- Boyle JG, Davidson DF, Perry CG, et al. Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. *J Clin Endocrinol Metab* 2007;92:4602–4608.
- Pacak K. Preoperative management of the pheochromocytoma patient. *J Clin Endocrinol Metab* 2007;92:4069–4079.
- Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. *Nat Clin Pract Endocrinol Metab* 2007;3:92–102.
- van der Harst E, de Herder WW, Bruining HA, et al. [(123I)]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. *J Clin Endocrinol Metab* 2001;86:685–693.
- Timmers HJ, Taieb D, Pacak K. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. *Horm Metab Res* 2012;44:367–372.
- Reisch N, Peczkowska M, Januszewicz A, et al. Pheochromocytoma: Presentation, diagnosis and treatment. *J Hypertens* 2006;24:2331–2339.
- Yip L, Lee JE, Shapiro SE, et al. Surgical management of hereditary pheochromocytoma. *J Am Coll Surg* 2004;198:525–534; discussion 534–535.
- Asari R, Scheuba C, Kaczirek K, et al. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. *Arch Surg* 2006;141:1199–1205; discussion 1205.
- Pilarski R. Cowden syndrome: A critical review of the clinical literature. *J Genet Couns* 2009;18:13–27.

59. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: Absence of clear genotype–phenotype correlations. *Eur J Hum Genet* 1999;7:267–273.
60. Nelen MR, Padberg GW, Peeters EAJ, et al. Localization of the gene for Cowden disease to 10q22-23. *Nat Genet* 1996;13:114–116.
61. Eng C. Will the real Cowden syndrome please stand up: Revised diagnostic criteria. *J Med Genet* 2000;37:828–830.
62. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. *J Med Genet* 2004;41:323–326.
63. Zbuk KM, Stein, JL, Eng C. PTEN Hamartoma Tumor Syndrome (PHTS). GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. <http://www.genetests.org>. Updated January 23, 2014. Accessed September 3, 2014.
64. Starink TM, van der Veep JPW, Arwert F, et al. The Cowden syndrome: A clinical and genetic study in 21 patients. *Clin Genet* 1986;29:222–233.
65. Starink TM. Cowden's disease: Analysis of fourteen new cases. *J Am Acad Dermatol* 1984;11:1127–1141.
66. Salem OS, Steck WD. Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. *J Am Acad Dermatol* 1983;8:686–696.
67. Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. *Gastroenterology* 2010;139:1927–1933.
68. Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: An evaluation of Cowden syndrome and Bannayan–Riley–Ruvalcaba syndrome clinical features. *J Med Genet* 2011;48:505–512.
69. Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 2012;18:400–407.
70. Tamguney T, Stokoe D. New insights into PTEN. *J Cell Sci* 2007;120:4071–4079.
71. Nelen MR, van Staveren CG, Peeters EAJ, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. *Hum Mol Genet* 1997;6:1383–1387.
72. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nat Genet* 1997;16:64–67.
73. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype–phenotype analyses in Cowden disease and Bannayan–Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. *Hum Mol Genet* 1998;7:507–515.
74. Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan–Riley–Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositide-3-kinase/Akt pathway. *Am J Hum Genet* 2003;73:404–411.
75. Chibon F, Primos C, Bressieux JM, et al. Contribution of PTEN large rearrangements in Cowden disease: A MAPH screening approach. *J Med Genet* 2008;45:657–665.
76. National Comprehensive Cancer Network. The NCCN Genetic Familial High-Risk Assessment: Breast and Ovarian (Version 1.2012). Accessed September 3, 2014.
77. Ni Y, Zbuk KM, Sadler T, et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. *Am J Hum Genet* 2008;83:261–268.
78. Bayley JP. Succinate dehydrogenase gene variants and their role in Cowden syndrome. *Am J Hum Genet* 2011;88:674–675; author reply 676.
79. Bennett KL, Mester J, Eng C. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. *JAMA* 2011;304:2724–2731.
80. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant pheochromocytomas. *Cancer Res* 2003;63:5615–5621.
81. Welander J, Soderkvist P, Gimmo O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. *Endocr Relat Cancer* 2011;18:R253–R276.
82. King KS, Prodanov T, Kantorovich V, et al. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: Significant link to SDHB mutations. *J Clin Oncol* 2011;29:4137–4142.
83. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. *JAMA* 2004;292:943–951.
84. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. *J Natl Cancer Inst* 2008;100:1260–1262.
85. Henderson A, Douglas F, Perros P, et al. SDHB-associated renal oncocyoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. *Fam Cancer* 2009;8:257–260.
86. Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. *Hum Mutat* 2010;31:41–51.
87. van der Mey AG, Maaswinkel-Mooy PD, Cornelisse CJ, et al. Genomic imprinting in hereditary glomus tumours: Evidence for new genetic theory. *Lancet* 1989;2:1291–1294.
88. Pigny P, Vincent A, Cardot Bauters C, et al. Paraganglioma after maternal transmission of a succinate dehydrogenase gene mutation. *J Clin Endocrinol Metab* 2008;93:1609–1615.
89. Yeap PM, Tobias ES, Mavraki E, et al. Molecular analysis of pheochromocytoma after maternal transmission of SDHD mutation elucidates mechanism of parent-of-origin effect. *J Clin Endocrinol Metab* 2011;96:E2009–E2013.
90. Schiavi F, Boedeker CC, Bausch B, et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. *JAMA* 2005;294:2057–2063.
91. Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. *Science* 2009;325:1139–1142.
92. Bayley JP, Kunst HP, Cascon A, et al. SDHAF2 mutations in familial and sporadic paraganglioma and pheochromocytoma. *Lancet Oncol* 2010;11:366–372.
93. Horvath R, Abicht A, Holinski-Feder E, et al. Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA). *J Neurol Neurosurg Psychiatry* 2006;77:74–76.
94. Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. *Hum Mol Genet* 2010;19:3011–3020.
95. Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. *J Clin Endocrinol Metab* 2011;96:E1472–E1476.
96. Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. *Nat Genet* 2010;42:229–233.
97. Yao L, Schiavi F, Cascon A, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. *JAMA* 2010;304:2611–2619.
98. Neumann HP, Sullivan M, Winter A, et al. Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. *J Clin Endocrinol Metab* 2011;96:E1279–E1282.
99. Abermil N, Guillaud-Bataille M, Burnichon N, et al. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. *J Clin Endocrinol Metab* 2012;97:E805–E809.
100. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. *Nat Genet* 2011;43:663–667.
101. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. *N Engl J Med* 2002;346:1459–1466.
102. Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. *J Clin Endocrinol Metab* 2009;94:2817–2827.
103. Jafri M, Maher ER. The genetics of pheochromocytoma: using clinical features to guide genetic testing. *Eur J Endocrinol* 2012;166:151–158.
104. Rubinstein WS. Endocrine cancer predisposition syndromes: Hereditary paraganglioma, multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 2, and hereditary thyroid cancer. *Hematol Oncol Clin North Am* 2010;24:907–937.
105. Maher ER, Iselius L, Yates JRW, et al. von Hippel-Lindau disease: a genetic study. *J Med Genet* 1991;28:443–447.
106. Neumann HPH, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. *Lancet* 1991;337:1052–1054.
107. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. *Eur J Hum Genet* 2011;19:617–623.
108. Maher ER, Eng C. The pressure rises: update on the genetics of pheochromocytoma. *Hum Mol Genet* 2002;11:2347–2354.
109. Gimenez-Roqueplo AP, Lehnert H, Mannelli M, et al. Pheochromocytoma, new genes and screening strategies. *Clin Endocrinol (Oxf)* 2006;65:699–705.
110. Eric Z, Rybicki L, Peczkowska M, et al. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. *Clin Cancer Res* 2009;15:6378–6385.